Hepion Pharmaceuticals, Inc.
(NASDAQ : HEPA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 1.87%58.366.5%$172.51m
CTLTCatalent, Inc. 1.87%75.112.1%$126.71m
JAZZJazz Pharmaceuticals Plc -0.04%108.742.4%$109.68m
VRXValeant Pharmaceuticals International, Inc. -2.98%17.8814.1%$105.21m
BHCBausch Health Cos., Inc. -3.12%17.860.0%$74.88m
UTHRUnited Therapeutics Corp. 0.69%119.4214.3%$71.08m
ICPTIntercept Pharmaceuticals, Inc. -1.17%44.8416.8%$61.07m
AXSMAxsome Therapeutics, Inc. 0.45%84.261.9%$53.48m
PRGOPerrigo Co. Plc -0.60%54.876.8%$49.27m
ZGNXZogenix, Inc. 1.27%27.937.5%$49.06m
MYOKMyoKardia, Inc. 1.29%95.251.8%$47.53m
PCRXPacira Biosciences, Inc. 0.48%54.4310.3%$45.02m
ARGXargenx SE 1.08%248.040.0%$43.05m
AMRNAmarin Corp. Plc -0.22%6.731.6%$40.81m
GWPHGW Pharmaceuticals Plc -0.93%128.426.2%$39.84m

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.